Related references
Note: Only part of the references are listed.A Pituitary Society update to acromegaly management guidelines
Maria Fleseriu et al.
PITUITARY (2021)
Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands
Maria Fleseriu et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Model informed quantification of the feed-forward stimulation of growth hormone by growth hormone-releasing hormone
Michiel J. Esdonk et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Pituitary-Tumor Endocrinopathies
Shlomo Melmed
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider
Eliza B. Geer et al.
PITUITARY (2020)
An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies
Maria Fleseriu et al.
PITUITARY (2020)
Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide
Susan L. Samson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update
Monica R. Gadelha et al.
ENDOCRINE REVIEWS (2019)
Acromegaly
Annamaria Colao et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly
Shuqian Liu et al.
JOURNAL OF INVESTIGATIVE MEDICINE (2018)
How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review
Michiel J. van Esdonk et al.
PITUITARY (2018)
The role of combination medical therapy in the treatment of acromegaly
Dawn Shao Ting Lim et al.
PITUITARY (2017)
Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial
Shlomo Melmed et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis
John D. Carmichael et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Acromegaly: An Endocrine Society Clinical Practice Guideline
Laurence Katznelson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
A. Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
A Novel Suspension Formulation Enhances Intestinal Absorption of Macromolecules Via Transient and Reversible Transport Mechanisms
Shmuel Tuvia et al.
PHARMACEUTICAL RESEARCH (2014)
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly-2011 Update
Laurence Katznelson et al.
Endocrine Practice (2013)
Oral Octreotide Absorption in Human Subjects: Comparable Pharmacokinetics to Parenteral Octreotide and Effective Growth Hormone Suppression
S. Tuvia et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review
Maria Fleseriu
PITUITARY (2011)
Normal values of serum IGF-1 in adults: results from a Brazilian population
Pedro Weslley Rosario
ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA (2010)
The use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: Physiological intra-individual variation of IGF-I, type 3 pro-collagen (P-III-P) and the GH-2000 detection score
Ioulietta Erotokritou-Mulligan et al.
CLINICAL ENDOCRINOLOGY (2010)
Within-subject variability and analytic imprecision of insulinlike growth factor axis and collagen markers: Implications for clinical diagnosis and doping tests
Tuan V. Nguyen et al.
CLINICAL CHEMISTRY (2008)
Variability and reliability of single serum IGF-I measurements: Impact on determining predictability of risk ratios in disease development
D Milani et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Circadian variation in serum free and total insulin-like growth factor (IGF)-I and IGF-II in untreated and treated acromegaly and growth hormone deficiency
C Skjaerbaek et al.
CLINICAL ENDOCRINOLOGY (2000)
Share Paper
